PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Investigate The Effect Of Erythromycin On The Pharmacokinetics Of PH-797804
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01589614
- Locations
- ๐ธ๐ฌ
Pfizer Investigational Site, Singapore, Singapore
TBE Seropersistence up to 10 Years After First Booster in Adults
- Conditions
- Tick-borne Encephalitis (TBE)
- Interventions
- Biological: FSME-IMMUN 0.5 ml
- First Posted Date
- 2012-04-23
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 243
- Registration Number
- NCT01582698
- Locations
- ๐ต๐ฑ
Prywatny Gabinet Lekarski, Dฤbica, Poland
๐ต๐ฑ"John Paul II" Cracow Specialist Hospital, Department of Pediatric Neuroinfections and Neurology, Krakow, Poland
Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01579903
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, London, United Kingdom
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 491
- Registration Number
- NCT01578850
- Locations
- ๐จ๐ฟ
PV-Medical s.r.o., Zlin, Czech Republic
๐ช๐ฌAin Shams University/Al Demerdash Hospital/Diabetology Unit, Cairo, Egypt
๐ช๐ฌNew University Hospital, Alexandria Clinical Research Center, Alexandria, Al Iskandariyah, Egypt
A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: 600 ceftaroline fosamil in 250 ml infusion volumeDrug: 600 mg ceftaroline fosamil in 50 ml infusion volumeDrug: Placebo in 50 ml infusion volumeDrug: Placebo in 250 ml infusion volumeDrug: 600 mg ceftaroline in 100 ml infusion volumeDrug: Placebo in 100 ml infusion volume
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT01577589
- Locations
- ๐ฌ๐ง
Research site, London, United Kingdom
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
- Conditions
- Age-Related Maculopathy
- Interventions
- Biological: PlaceboBiological: RN6G
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT01577381
- Locations
- ๐บ๐ธ
Apothecary By Design, Portland, Maine, United States
๐บ๐ธCardiology Consultants of Long Island, PC- Physical Exam Facility Only, Rockville Centre, New York, United States
๐บ๐ธSouth Carolina Neurological Clinic (Neurological Exams Only), West Columbia, South Carolina, United States
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT01576406
- Locations
- ๐บ๐ธ
The Emory Clinic, Atlanta, Georgia, United States
๐บ๐ธLAC&USC Medical Center, Los Angeles, California, United States
๐บ๐ธKeck Hospital of USC, Los Angeles, California, United States
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
- Conditions
- Smoking Cessation
- Interventions
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4595
- Registration Number
- NCT01574703
- Locations
- ๐จ๐ฆ
Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada
๐ง๐ฌUMHAT "Dr. Georgi Stranski" Ltd., Pleven, Bulgaria
๐ง๐ฌUMHAT "Sveti Georgi" Ltd., Plovdiv, Bulgaria
A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment
- Conditions
- HealthyOtherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT01571388
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, South Miami, Florida, United States
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain
- Conditions
- AnalgesiaLow Back PainChronic Pain
- Interventions
- Drug: PlaceboDrug: ALO-02
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 410
- Registration Number
- NCT01571362
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials, LLC, Anaheim, California, United States
๐บ๐ธNeuro-Pain Medical Center, Fresno, California, United States
๐บ๐ธThe Office of Martin E. Hale, MD, PA, Plantation, Florida, United States